The results of an international multi-center clinical study have been confirmed by the People's Liberation Army 307 Hospital. The use of micro-transplantation for the treatment of senile leukemia is significantly more effective than traditional transplantation and chemotherapy. Related research results were published in the US authoritative journal "American Medical Association Journal - Oncology" in September this year. The study looked at the efficacy of micro-transplantation in 185 elderly patients with acute myeloid leukemia from China, the United States, and Spain. The results showed that the complete remission rate of leukemia in these patients was as high as 74.6%, and the 2-year overall survival rate was 50.2%. The incidence of infection and organ failure was only 8% and 2.2%, respectively. In the absence of preventive measures, only 1.1% of patients developed acute graft-versus-host disease (rejection) symptoms. This is the first international multi-center clinical study conducted by the International Micro-Porting Interest Research Group led by Ai Huisheng, director of the Department of Hematology, 307 Hospital of the People's Liberation Army. The relevant data are from 15 research centers in China, the United States and Spain. Different countries, races, and aging, followed up for two years, comprehensively tested and confirmed the excellent efficacy of micro-transplantation. Micro-transplant technology raises the efficacy of senile leukemia to a new level and provides a safer and more effective cure for more patients. Ai Huisheng is the first international scholar to conduct clinical research on leukemia micro-transplant therapy. Related research results have been published in the US authoritative journals "Blood" and "Clinical Oncology", and micro-transplant technology has been gradually applied at home and abroad. Up to now, the "International Micro-Transplantation Collaboration Group" sponsored by Ai Huisheng, editor of Bob Lewinberg, editor of the US "Blood" magazine, and Nathan Cao, Duke University, USA, and Ai Huisheng. The International Micro-Transplant Interest Research Group has joined 42 research centers in North America, Europe, Australia, and Asia to regularly discuss micro-transplant clinical and basic research issues, share research experience, and collaborate on clinical research. Driven by the above two working groups, the enthusiasm for the research on the clinical application and mechanism of micro-transplantation has been rising steadily. Many blood and transplantation centers in the United States, Canada, Australia and other countries have applied micro-transplant technology to treat acute leukemia. , myelodysplastic syndrome, lymphoma, myeloma, solid tumors and other diseases. In practical applications, the technology has shown many advantages such as improving patient prognosis, accelerating hematopoietic recovery after chemotherapy, shortening the period of bone marrow suppression, and exerting anti-tumor efficacy. (People's Daily) Insulin Syringes Needle,Disable Syringe,Monoject Syringe,10 Ml Syringe FOSHAN PHARMA CO., LTD. , https://www.pharmainjection.com